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The GH dose-response effect of long-term continuous GH
treatment on adult height (AH) was evaluated in 54 short
children born small for gestational age (SGA) who were par-
ticipating in a randomized, double-blind, dose-response trial.
Patients were randomly and blindly assigned to treatment
with either 3 IU (group A) or 6 IU (group B) GH/m2d (0.033
or 0.067 mg/kgd, respectively). The mean (SD) birth length
was3.6 (1.4), the age at the start of the study was 8.1 (1.9) yr,
and the height SD score (SDS) at the start of the study 3.0
(0.7). Seventeen of the 54 children were partially GH deficient
(stimulated GH peak, 10–20 mU/liter). Fifteen non-GH-
treated, non-GH-deficient, short children born SGA, with sim-
ilar inclusion criteria, served as controls [mean (SD) birth
length, 3.3 (1.2); age at start, 7.8 (1.7) yr; height SDS at start,
2.6 (0.5)]. GH treatment resulted in an AH above 2 SDS in
85% of the children after a mean (SD) GH treatment period of
7.8 (1.7) yr. The mean (SD) AH SDS was 1.1 (0.7) for group A
and0.9 (0.8) for group B, resulting from a mean (SD) gain in
height SDS of 1.8 (0.7) for group A and 2.1 (0.8) for group B. No
significant differences between groups A and B were found for
AH SDS (mean difference, 0.3 SDS; 95% confidence interval,
0.2, 0.6; P > 0.2) and gain in height SDS (mean difference, 0.3
SDS; 95% confidence interval, 0.1, 0.7; P > 0.1). When cor-
rected for target height, the mean corrected AH SDS was0.2
(0.8) for group A and0.4 (0.9) for group B. The mean (SD) AH
SDS of the control group [2.3 (0.7)] was significantly lower
than that of the GH-treated group (P < 0.001). Multiple re-
gression analysis indicated the following predictive variables
for AH SDS: target height SDS, height SDS, and chronological
age minus bone age (years) at the start of the study. GH dose
had no significant effect. In conclusion, long-term continuous
GH treatment in short children born SGA without signs of
persistent catch-up growth leads to a normalization of AH,
even with a GH dose of 3 IU/m2d (0.033 mg/kgd). (J Clin
Endocrinol Metab 88: 3584–3590, 2003)
TO BE BORN small for gestational age (SGA) may haveconsiderable consequences. Not only has a signifi-
cantly increased risk for reaching an adult height (AH) below
2 sd score (SDS) been reported (1), but there might also be
an increased risk for diabetes mellitus type 2 and cardiovas-
cular disease, as has been described in adults with a low birth
weight (2). It is as yet unclear whether this will also be true
for SGA patients with persistent short stature, as no distinc-
tion was made for those who had complete catch-up growth
in height after birth and those with persistent short stature.
During the first 2 yr of life, about 15% of the children born
SGA do not catch-up to a height above2 SDS. The majority
of these children will reach an AH below 2 SDS (2, 3). The
reason for these children remaining short is not completely
understood. Sixty percent of short children born SGA have
low serum GH levels during a 24-h GH profile, but no re-
lation was found between physiological GH levels and the
growth response during GH treatment (4–6). There are sev-
eral theories to explain their persistent short stature. One
suggests that it is the result of a reduced sensitivity for
growth factors; another suggests that it might be influenced
by intrauterine reprogramming or genetic background (7–9).
Recent studies have demonstrated that 5 yr of GH treatment
in short children born SGA results in a normalization of
height during childhood (6, 10). AH results after long-term,
continuous GH treatment, however, have not yet been
published.
In this article we present AH results of 54 short children
born SGA who were treated in a randomized, double-blind,
dose-response GH trial evaluating the efficacy and safety of
long-term, continuous GH treatment with either 3 or 6 IU
GH/m2d (0.033 or 0.067 mg/kgd).
Subjects and Methods
Study group
Seventy-nine prepubertal short children born SGA participated in a
multicenter, double-blind, randomized, dose-response GH trial. Of
these 79 children, six children dropped out of the study for the following
reasons: lack of motivation despite ongoing catch-up growth (n  4),
treatment for precocious puberty (n  1), and biochemical signs of GH
insensitivity (n  1). As these six children were lost to follow-up, their
Abbreviations: AH, Adult height; ATT, arginine tolerance test; BA,
bone age; BMI, body mass index; CA, chronological age; CI, confidence
interval; GHD, GH deficiency; HV, height velocity; PI, prediction in-
terval; SDS, sd score; SGA, small for gestational age; TH, target height.
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data were not included in the analysis. Of the remaining 73 children, 54
children reached AH, and their data were evaluated for this study,
whereas 19 children were not included because they had not yet reached
AH. Those who had attained AH were approximately 3 yr older at the
start of GH treatment compared with those who were still growing
[mean (sd) chronological age (CA), 8.1 (1.9) vs. 5.4 (1.9) yr; P  0.001],
but the other clinical characteristics were similar at the start of GH
treatment (Table 1).
The dose-response GH trial evaluated the effect of two dosages of GH,
3 and 6 IU GH/m2 body surfaced (0.033 or 0.067 mg/kgd), on long-
term growth and ultimately on AH. Inclusion criteria were 1) birth
length SDS below 1.88 (11), 2) CA between 3–11 yr in boys and 3–9 yr
in girls at the start of the study, 3) height SDS for CA (height SDS) below
1.88 (12), 4) height velocity (HV) SDS for CA zero or less (12) to exclude
children presenting spontaneous catch-up growth, 5) prepubertal stage
(defined as Tanner breast stage I for girls and a testicular volume4 ml
for boys) (13), 6) uncomplicated neonatal period [that is, without signs
of severe asphyxia (defined as an Apgar score 3 after 5 min), without
sepsis neonatorum, and without long-term complications of respiratory
ventilation]. Exclusion criteria were endocrine or metabolic disorders,
chromosomal disorders, growth failure caused by other disorders (emo-
tional deprivation, severe chronic illness, or chondrodysplasia) or syn-
dromes (except for Silver-Russell syndrome) and previous or present use
of drugs that could interfere with GH treatment. Twenty-seven of the 79
patients had partial GH deficiency (GHD), which was defined as a
maximal peak GH secretion between 10–20 mU/liter during two GH
provocation tests or during one provocation test and a 24-h GH profile
(5, 14).
The GH trial started in 1991 and was approved by the ethics com-
mittees of the four participating centers in The Netherlands. Due to
ethical considerations the ethics committees did not allow for a control
group until AH. Written informed consent was obtained from the par-
ents or guardians of each child.
Control group
In 1990, 107 children born in three academic hospitals with a birth
length below1.88 SDS in the same time period as the GH-treated group
(1980 until 1989), were included in a cohort study to evaluate natural
growth in SGA children with short stature at the age of 2 yr (3). Fifty-nine
children were lost due to either start of GH treatment (n 21), treatment
for precocious puberty (n  1), spastic paraplegia (n  1), or lack of
motivation or moving abroad (n  36). During the inclusion period of
the GH trial, 29 children met the inclusion criteria of our GH trial,
including persistent short stature without signs of catch-up growth (HV
SDS,0), but they remained untreated because their pediatrician did not
participate in the GH trial. None of these children was GH deficient. This
group was followed as a control group for the GH trial. In 2001, 15
children had reached AH and served as controls for comparison of
growth and AH of the 54 GH-treated children.
Design dose-response GH trial
After stratification for CA and spontaneous GH secretion during a
24-h GH profile, 79 children were randomly and blindly assigned to one
of two GH dosage groups: group A, 3 IU/m2d; or group B, 6 IU/m2d
(0.033 or 0.067 mg/kgd, respectively) (5, 6). The inclusion period
started in April 1991 and ended in January 1993. Biosynthetic GH (r-hGH
Norditropin, Novo Nordisk A/S, Copenhagen, Denmark) was given sc
once daily at bedtime with a pen injection system (Nordiject 24). Every
3 months the total GH dose was adjusted to the calculated body surface.
To ensure the double-blind design, an equal volume of a reconstituted
preparation was used.
Growth evaluation
During 11 yr one physician (from 1991–1995, W. de Waal; from
1995–1998, T. Sas; from 1998–2002, Y. van Pareren) examined all children
every 3 months and measured height according to Cameron using a
Harpenden stadiometer (15). Four measurements per visit were taken,
and the mean was used for analysis. Height was expressed as the
SDS for CA (height SDS) (12). Target height (TH) was adapted from
Dutch reference data with the addition of 3 cm for secular trend: 1/2 
(heightfather  heightmother  12)  3 for boys and 1/2  (heightfather 
heightmother 12) 3 for girls (12). TH and body mass index (BMI) were
expressed as the SDS using Dutch references (12). TH range was defined
as the mean TH  2 SD. Bone age (BA) was determined by the same
investigators (1991–1998, T. Sas; 1998–2001, Y. van Pareren) according
to the Tanner and Whitehouse radius, ulna, short bones score (RUS
TW-2) (16). Bone maturation was expressed as the ratio of the change in
BA to the change in CA. The difference between CA and BA was
calculated as CA minus BA (CA BA) in years. The same investigators
assessed pubertal stage according to Tanner, using an orchidometer in
boys. The start of puberty was defined as a Tanner breast stage II in girls
and a testicular volume of 4 ml in boys (13).
Definition of AH
AH in GH-treated children was defined as the condition when HV
had dropped less than 0.5 cm during the previous 6 months and bone
age was 15 yr or greater for girls and 16.5 yr or greater for boys. AH was
reached either during GH treatment or during the 2-yr follow-up after
discontinuation of GH treatment. Corrected AH was calculated by sub-
tracting the target height (TH) SDS from the AH SDS. GH treatment was
discontinued after reaching AH or on the patient’s decision at near AH
(near AH), which was defined as a HV ranging between 0.5–2 cm during
the previous 6 months. For the control group, AH was defined as the
condition when CA and/or BA had reached 18 yr for boys and 16 yr in
girls.
Biochemical parameters
Before the start and after discontinuation of GH treatment a standard
arginine tolerance test (ATT) was performed (5). A standard oral glucose
tolerance test was performed at the start of GH treatment and after 6 yr
of GH treatment (17). At the start of GH treatment and during the
dose-response GH trial additional blood samples were taken for deter-
mination of plasma levels of IGF-I and hemoglobin A1c levels. Plasma
levels of IGFBP-3 were determined at the start of GH treatment and after
the first and second years and after the fifth year of GH treatment. After
centrifugation, all samples were frozen (20 C) until assayed.
TABLE 1. Baseline clinical data for the total group of 79 short children born SGA and for the 54 children who reached AH









Male/female 31/10 21/17 18/10 14/12
Gestational age (wk) 37.3 (3.2) 36.0 (4.1) 37.1 (3.4) 36.2 (4.3)
Birth length SDS 3.6 (1.4) 3.7 (1.7) 3.5 (1.3) 3.6 (1.5)
Birth weight SDS 2.6 (1.2) 2.6 (1.0) 2.6 (1.1) 2.6 (0.8)
CA (yr) 6.6 (2.4) 6.7 (2.9) 7.9 (1.9)a 8.2 (1.9)a
Height SDS 3.0 (0.7) 3.1 (0.7) 2.9 (0.8) 3.0 (0.7)
HV SDS 0.7 (1.1) 1.2 (1.3) 0.6 (1.1) 1.4 (1.4)
Data are expressed as the mean (SD).
a P  0.001, mean (SD) CA of 54 children with AH [8.1 (1.9)] vs. 19 who were still growing [5.4 (1.9)].
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Hormone assays
RIA measurements of plasma GH, IGF-I, IGFBP-3, and insulin were
performed as described previously (18–21). All measurements were
performed in the same laboratories. As plasma levels of both IGF-I and
IGFBP-3 are dependent on age and sex, values were transformed to SDSs
using reference values for healthy children determined in the same
laboratory (22).
Statistical analyses
To maintain the double-blind design until all participants reached
AH, an independent statistician (P.M.) performed the statistical analyses
and summarized the results per treatment group in such a way that it
was impossible for the investigator to identify individual patients. Ac-
cordingly, data are expressed as mean (sd) values unless otherwise
specified. Differences in continuous variables were tested by paired t
tests. Differences between zero and SDS values at various time points
during the study were tested by one-sample t tests. Differences between
groups were tested using a two-sample t test. To test for relationships
between continuous variables, correlations were estimated after adjust-
ment for GH dosage. Multiple linear regression analyses were used to
construct the best model for predicting AH SDS. For this purpose, the
variables GH dose, TH SDS, height SDS at the start of GH treatment,
CA  BA at the start of GH treatment, birth length SDS, gender, CA at
the start of the study, bone maturation during the first year, age at onset
of puberty, and BMI SDS at the start were tested. P 0.05 was considered




Fifty-four children reached AH after a mean (sd) GH
treatment period of 7.9 (1.7) yr for group A and 7.5 (1.7) yr
for group B. Pretreatment clinical data are listed in Table 1
for the total group and for the 54 children who reached AH.
Both groups had similar clinical characteristics at the start of
GH treatment, except for age.
AH
GH treatment resulted in a mean (sd) AH SDS of 1.1
(0.7) for group A (3 IU/m2d) and 0.9 (0.8) for group B (6
IU/m2d; Table 2). In both groups, the AH SDS was signif-
icantly higher than the height SDS at the start of GH treat-
ment (P 0.0001). The difference in AH SDS between groups
A and B did not reach significance [mean difference, 0.3 SDS;
95% confidence interval (CI), 0.2, 0.6; P  0.3]. Figure 1
gives the height SDS at the start of the study, after 2 and 5
yr of GH treatment, and at AH and the gain in height SDS
from the start until AH. The mean (sd) gain in height SDS
from the start until AH was not significantly different for
group A [from2.9 (0.8) at start to1.1 (0.7)] compared with
group B [from 3.0 (0.7) to 0.9 (0.8); mean difference, 0.3
SDS; 95% CI, 0.1, 0.7; P  0.1]. Table 2 lists the height SDS
throughout the study, TH SDS, AH SDS, and the corrected
AH SDS (AH SDS minus TH SDS). The mean (sd) TH SDS
was almost significantly lower for group A [0.9 (1.0)] than
for group B [0.5 (0.9); mean difference, 0.5; 95% CI, 0.1, 1.0;
P 0.08]. As a result the mean (sd) corrected AH SDS was
not significantly different between group A [0.2 (0.8)] and
group B [0.4 (0.9); mean difference, 0.2; 95% CI, 0.2, 0.7;
P  0.2]. Figure 2 shows the corrected height SDS at the
various time points of the study. At the start and after 2 yr
of GH treatment, the corrected height SDS was significantly
less than zero for groups A and B (P  0.001 and P  0.001,
respectively). At AH, the corrected height SDS was compa-
rable to zero for group A, but was lower for group B (P 
0.05). For boys, both TH SDS and AH SDS were significantly
higher for group B than for group A (P 0.01, P 0.05, and
P  0.05, respectively; Table 2). For girls, however, no dif-
ference was found for TH SDS and AH SDS between groups
A and B (P  0.1).
TABLE 2. AH SDS and other auxological data in 54 SGA children at various time points during the study













Duration of GH treatment (yr) 7.9 (1.7) 7.5 (1.7) 8.1 (1.9) 7.6 (1.8) 7.7 (1.5) 7.2 (1.2)
Height SDS
At start 2.9 (0.8) 3.0 (0.7) 2.9 (0.7) 3.0 (0.8) 3.0 (0.8) 3.1 (0.3)
2 yr 1.5 (0.7) 1.3 (0.7) 1.5 (0.7) 1.3 (0.8) 1.5 (0.7) 1.3 (0.3)
5 yr 0.7 (0.7) 0.7 (0.8) 0.7 (0.7) 0.6 (0.8) 0.8 (0.6) 0.9 (0.7)
AH 1.1 (0.8) 0.9 (0.8) 1.1 (0.8) 0.9 (0.8) 1.2 (0.7) 0.8 (0.7)
Corrected height SDS
(height SDS  TH SDS)
At start 2.0 (0.9) 2.6 (0.6)a 2.2 (0.9) 2.7 (0.9) 1.9 (0.9) 2.2 (0.4)
2 yr 0.6 (0.9) 0.0 (0.8) 0.7 (1.0) 1.0 (0.9) 0.4 (0.9) 0.3 (0.4)
5 yr 0.2 (0.8) 0.2 (1.0) 0.1 (0.9) 0.3 (1.1) 0.4 (0.8) 0.0 (0.4)
AH 0.2 (0.8) 0.4 (0.9) 0.3 (0.8) 0.8 (1.0) 0.1 (0.7) 0.0 (0.2)b
TH SDS 0.9 (1.0) 0.5 (0.9) 0.8 (1.0) 0.3 (0.9) 1.1 (0.9) 0.9 (0.6)
Adult height (cm)
Boys 169.3 (6.7) 173.7 (5.8)
Girls 160.1 (3.1) 159.2 (4.0)
Pubertal height gain (cm)
Boys 27.3 (7.6) 30.0 (5.3)
Girls 18.8 (6.9) 19.4 (5.8)
Data are expressed as the mean (SD). Data on AH (centimeters) and pubertal height gain (centimeters) for non-GHD vs. GHD are not shown
due to the small number of children in each subgroup.
a P  0.05, group A vs. group B.
b P  0.05, non-GHD vs. partially GHD children.
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AH of non-GHD vs. partially GHD SGA children
The AH SDS of the non-GHD children was 1.1 (0.8) for
group A and0.9 (0.8) for group B compared with1.2 (0.7)
for group A and 0.9 (0.7) for group B in the partially GHD
children (Table 2). The mean height gain SDS of the non-
GHD children was 1.9 (0.8) for group A and 2.1 (0.8) for
group B, compared with 1.8 (0.5) for group A and 2.2 (0.6) for
group B in the partially GHD children. The AH SDS as well
as the height gain SDS were not significantly different be-
tween the non-GHD and the partially GHD SGA children,
even when corrected for GH dose and TH SDS.
Puberty
The mean (sd) age at onset of puberty for boys was 11.7
(0.9) yr in group A and 11.8 (0.7) yr in group B, and that for
girls was 10.9 (1.1) yr in group A and 10.8 (1.1) yr in group
B, without a significant difference between the GH dosage
groups (P 0.1 for both sexes). For boys, the mean age (sd)
at AH was 16.8 (0.9) yr in group A vs. 16.9 (1.1) yr in group
B, and for girls, it was 14.8 (0.8) yr vs. 15.1 (1.2) yr in groups
A and B, respectively. The age at AH was not different
between the GH dosage groups (P 0.1 for both sexes). The
mean duration of puberty (from the start of puberty until
AH) for boys was 5.1 (1.2) yr in group A and 5.2 (1.0) yr in
group B, and that for girls was 3.9 (1.0) yr in group A and 4.3
(1.1) yr in group B.
Bone maturation
The average bone maturation, expressed as change in
(	)BA/	CA per year, was throughout the study significantly
higher than 1 regardless of GH dosage. During the first year
of GH treatment, the median (range) bone maturation was
1.5 (0.6–2.7) yr for group A and 1.1 (0.2–3.2) yr for group B.
From 4–5 yr of GH treatment, bone maturation was 1.1
(0.3–2.5) yr for group A and 1.0 (0.3–2.2) yr for group B, and
from 5 yr until discontinuation of GH treatment, bone mat-
uration was 1.0 (0.3–1.6) yr for group A and 1.1 (0.4–1.7) yr
for group B. The average differences between CA and BA
(CA  BA) at the start of GH treatment, at 5 yr of GH
treatment, and at discontinuation of GH treatment were 0.5
(1.1), 1.0 (1.1), and 1.1 (1.1), respectively, without signif-
icant differences between groups A and B.
GH, IGF-I, and IGFBP-3
The non-GHD SGA children who attained AH had at the
start of GH treatment a mean (sd) maximal GH peak dur-
ing a GH provocation test of 28.7 (11.5) mU/liter, a mean
(sd) GH peak during the 24-h GH profile of 37.2 (16.1)
mU/liter, and a mean IGF-I SDS of 0.5 (0.8). Seventeen of
the 54 SGA children who attained AH had a maximal GH
peak between 10–20 mU/liter. In these partially GHD SGA
children, the mean (sd) maximal GH peak during the GH
provocation test, the GH peak during the 24-h GH profile,
and the mean IGF-I SDS at the start of treatment were 13.0
(5.8) mU/liter, 20.9 (8.5) mU/liter, and 1.8 (1.2), respec-
tively; all were significantly lower than in the non-GHD SGA
children (P  0.001, P  0.01, and P  0.001, respectively).
The changes in IGF-I SDS and IGFBP-3 SDS of the total
group during 5 yr of GH treatment were described previ-
ously (6). At discontinuation of GH treatment, the mean
IGF-I SDS was 1.0 (1.1) for group A and 1.3 (1.2) for group
B, being significantly different from zero for both groups
(P  0.001 for both). The mean IGFBP-3 SDS at discontinu-
ation of GH treatment was0.8 (0.9) for group A and0.06
(0.7) for group B, being significantly lower than zero for
group A only (P  0.001). Only for IGFBP-3 SDS was the
difference between groups A and B at discontinuation of GH
treatment significant (P  0.01).
FIG. 1. Bottom panel, Height SDS (SD) during GH treatment and at
AH in relation to TH. Top panel, Gain in height SDS (SD) from the
start until 2 yr of GH treatment, until 5 yr of GH treatment, and until
AH. , Group A; f, group B.
FIG. 2. Corrected height SDS (SD) during GH treatment and at AH
for group A () and group B (f).
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Predictors of AH
All correlations were made for groups A and B together,
after adjustment for GH dose, although no significant dif-
ferences in AH SDS and gain in height SDS were found
between groups A and B. The AH SDS correlated positively
with height SDS at the start of GH treatment (r  0.49; P 
0.001), TH SDS (r  0.49; P  0.001), and pretreatment HV
SDS (r  0.32; P  0.05). The AH SDS was not significantly
related to the following variables: CA and BA at the start of
GH treatment, birth length SDS, maximal GH peak during
ATT, characteristics of the 24-h GH profiles, IGF-I SDS values
at the start of GH treatment, and increment in IGF-I SDS
during the first year of GH treatment.
The gain in height SDS from the start of GH treatment until
AH had a negative correlation with CA and BA at the start
of GH treatment (r0.36; P 0.01 and r0.46; P 0.01,
respectively). Birth length SDS, TH SDS, pretreatment HV
SDS, IGF-I SDS at the start of GH treatment, increase in IGF-I
SDS, mean maximal plasma GH response during ATT, and
characteristics of the 24-h GH profiles did not correlate sig-
nificantly with the gain in height SDS from the start of GH
treatment until AH.
Multiple regression analysis showed that a model, using
the variables TH SDS, height SDS at the start of GH treat-
ment, CABA at the start of GH treatment, and the GH dose
accounted for 42% (residual sd, 0.60) of the variation in AH
SDS. Table 3 shows the results of the multiple regression
analysis. Variables that showed a nonsignificant effect on AH
SDS were gender, CA at start of treatment, bone maturation
during the first year, age at onset of puberty, BMI SDS at start
of treatment, birth length SDS, and GH dose. The model
provided the following equation: AH SDS  0.02  0.29 
TH SDS  0.42  height SDS at start  0.20  (CA  BA in
years) at start  0.07  GH dose.
Safety
Treatment was well tolerated, and no adverse events were
detected that were considered to be GH related. Our group
has recently published 6-yr results on fasting and stimulated
glucose and insulin levels during an oral glucose tolerance
test (17). In short, continuous GH treatment over a 6-yr pe-
riod had no adverse effect on glucose levels. GH treatment
induced higher fasting insulin levels and glucose-stimulated
insulin levels, indicating relative insulin resistance. No sig-
nificant differences between the two GH dosage groups were
found. None of the children developed diabetes mellitus.
Control group
The control group, 15 children (5 boys and 10 girls), had
a mean (sd) birth length SDS of 3.3 (1.2), a birth weight
SDS of2.7 (0.7), and a mean (sd) gestational age of 34.3 (2.3)
wk. At inclusion in the control group, the mean (sd) age
was 7.8 (1.7) yr, height SDS was2.6 (0.5), TH SDS was1.1
(1.0), and corrected height SDS was1.5 (0.9). No significant
difference was found between the GH-treated group and the
control group in pretreatment clinical characteristics, except
for gestational age (P  0.05).
AH of GH-treated vs. control group
The control group attained a mean (sd) AH SDS of2.3
(0.7) after a mean (sd) follow-up of 7.5 (1.2) yr from inclu-
sion in the control group until AH. The mean (sd) gain in
height SDS until AH was 0.3 (0.7) SDS, and the corrected AH
was 1.2 (0.6) SDS. The mean AH SDS, gain in height SDS
until AH, and corrected AH SDS were all significantly lower
than those in the GH-treated group [mean differences (95%
CI), 1.3 (0.9, 1.8), 1.7 (1.3, 2.3), and 0.9 (0.4, 1.4), respectively;
P  0.001 for all].
Discussion
Our study shows that in short children born SGA, long-
term continuous treatment with GH results in a normaliza-
tion of height during childhood and a normalization of AH
in most children. After a mean duration of 7.8 yr, children
treated with 3 IU GH/m2d (group A) attained a mean (sd)
AH SDS of 1.1 (0.7), whereas those treated with 6 IU GH/
m2d (group B) attained a mean AH SDS of 0.9 (0.8). GH
treatment resulted in an AH within the normal range (above
2.0 SDS) in 85% of the children and an AH within the TH
range in 98%. Interestingly, AH SDS was not significantly
different between the two GH dosage groups. Also, the mean
gain in height SDS from the start of treatment until AH [1.8
(0.7) SDS (an improvement of 12 cm for boys and 11 cm
for girls) for group A and 2.1 (0.8) SDS (an improvement of
14 cm for boys and 13 cm for girls) for group B] was not
significantly different between the two GH dosage groups.
When we corrected AH SDS for TH SDS, because group
A had a significantly lower TH SDS than group B, the mean
corrected AH SDS (AH SDS minus TH SDS) proved to be
comparable for group A [0.2 (0.8)] and group B [0.4 (0.9)].
This means that when AH SDS was corrected for the genetic
potential (TH), children who had been treated with the lower
GH dose of 3 IU/m2d had the same results. Our study shows
that 98% of short children born SGA treated with long-term
GH reached an AH within their TH range.
Two nonrandomized studies reported on AH in a group
of short children born SGA with GHD (23, 24). They found
a mean height SDS gain from start of the study until AH of
0.5 and 0.9 SDS, which is much lower than we now report.
There are, however, several factors that can explain the dis-
crepancy between their results and ours. Their children were
older (10.9 and 10.7 yr) at the start and were treated for a
much shorter period than our children (4.6 yr for both stud-
ies). In addition, in the study by Coutant et al. (23) children
were treated with a wide range of GH dosages and with a low
mean GH dose of 1.8 IU/m2d (almost half of our lowest GH
dose).
Because including a randomized control group as part of
our GH trial until AH was not allowed by the medical ethics
TABLE 3. Multiple regression analysis on AH SDS
Independent variable Regressioncoefficient SE P value
TH SDS 0.29 0.10 0.01
Height SDS at start 0.43 0.14 0.01
Difference CA-BA at start (yr) 0.20 0.08 0.05
GH dose (3 vs. 6 IU/m2/day) 0.07 0.06 0.2
Regression equation: AH SDS  0.02  0.29  TH SDS  0.43 
height SDS at start  0.20  (CA-BA) at start  0.07  GH dose.
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committees, we compared our GH-treated patients with a
longitudinally followed control group with the same inclu-
sion criteria and age as the GH-treated patients at the start
of treatment who did not receive GH treatment because the
pediatrician did not participate in the GH trial. The control
group attained a mean (sd) AH SDS of 2.3 (0.7), had a
mean gain in height SDS of 0.3 (0.7) until AH during the
follow-up period of 7.5 yr, and had a corrected AH of 1.2
(0.6) SDS. These data show that compared with untreated
short children born SGA, those treated with GH significantly
gained in AH SDS. The proportion of girls in the control
group, however, was larger than that in the GH groups. It is
unlikely that this will affect the results, as we show that AH,
expressed as SDS, did not differ between genders.
Our study demonstrates that most children reached a nor-
mal height after the first years of GH treatment and remained
in the normal range until AH. This means that most of them
had a normal height during childhood and puberty. At the
end of GH treatment, a slight decrease in height SDS was
found in comparison with height SDS after 5 yr of GH treat-
ment. Possible explanations for this decline might be an early
onset of puberty, a short duration of puberty, and/or an
acceleration of bone maturation. This would lead to attain-
ment of AH at a relatively young age compared with peers
and/or a reduced pubertal height gain. We found, however,
that for both GH dosage groups, the mean age at onset of
puberty was comparable to that in normal Dutch children
(median age for healthy boys is 11.5 yr and for girls is 10.7
yr), whereas from the onset of puberty until AH the mean
pubertal height gain was 29.8 cm for boys and 18.9 cm for
girls (25). In accordance, during puberty, no acceleration of
bone maturation was found until discontinuation. Previous
publications have shown, however, that untreated children
born SGA start their pubertal growth spurt earlier than nor-
mal children (26, 27). We found that the difference between
CA and BA (CA  BA) after 5 yr of GH treatment was 1.0,
indicating a 1-yr bone age advance. This might explain the
slight decrease in height SDS. As we found no significant
difference between the two GH dosage groups, it is unlikely
that the 1-yr bone age advance was related to the GH treat-
ment. Another factor that might explain the decrease in
height SDS is that some of the children did not reach their full
height potential because they stopped GH treatment at
near-AH.
AH SDS, when corrected for GH dosage, was higher in
children with the highest TH SDS and height SDS at start of
GH treatment. Although age at the start of treatment was
weekly correlated with height gain from the start of treat-
ment until AH, it was not associated with AH SDS. Why
other studies did find an association might be explained by
the fact that they started treatment at a later mean CA, which
implied a shorter duration of GH treatment (4.6 yr) until AH
than in our group (23). Over the long-term, other factors that
influence AH (i.e. genetic background) might become more
important. In our opinion, however, this should not lead to
postponing GH treatment until puberty. Not only would the
treatment period then be too short, but the important ad-
vantages of a normal height during childhood and adoles-
cence would be lost.
The GHD children included in our study were not severely
GHD, but only partially GHD. Their growth and AH results
were similar to those without GHD. Also, in the total study
group no correlation was found between spontaneous or
stimulated GH secretion before the start of GH treatment and
AH SDS or gain in height SDS. Our findings agree with other
reports showing no association between response to GH
treatment and GH status before start (28, 29). This indicates
that GH treatment is effective in short children born SGA,
leading to a normal AH for most of them regardless of the
GH status at start.
The recommended GH dose will depend on the ultimate
goal in short children born SGA. First, one might aim for a
normal AH, meaning an AH above 2 SDS. Secondly, one
could set out for an AH within the TH range SDS. To visu-
alize the effects of each of these goals on the decision of which
GH dose to use, we constructed a prediction model (Table 3).
The prediction model for AH SDS shows that several vari-
ables influence AH SDS: TH SDS, height SDS at the start of
treatment, and CA  BA at the start of treatment. For all of
these variables a higher value predicts an increment in AH
SDS. These variables are not surprising, as they have also
been found to predict height gain and AH in other patient
groups, but they indicate that similar factors play a role in
response to GH treatment in short SGA children (30, 31).
Suppose a child born SGA starts GH treatment when he or
she has a persistent short height of2 SDS and no BA delay
(CA  BA  0; Table 4). Our model then predicts that when
this child has an average TH SDS (TH SDS  0) it would
achieve an AH of0.6 SDS after a dose of 3 IU GH/m2d [95%
prediction interval (PI) between 1.8 and 0.6 SDS]. For a
child with a TH SDS of 2 treated with the same GH dose,
the predicted AH would be 1.2 SDS (95% PI between 2.4
and 0). When one chooses the first goal, an AH above2 SDS,
both children can be given 3 IU GH/m2d. When one decides
on the second goal, an AH near the TH SDS, a higher GH dose
of 6 IU GH/m2d might be considered for a child with a
higher TH SDS. Our model, however, shows that by giving
the child with a TH of 0 SDS the higher dose, the predicted
AH SDS would only increase by 0.2 SDS (0.4 SDS with 95%
PI between 1.6 and 0.8), while doubling the costs of treat-
ment. Another possible reason for considering a higher GH
dose could be when the child is very short at the start of GH
treatment. The model shows that, using the same values as
before (no BA delay and TH SDS  0), a child with a height
SDS at the start of GH treatment of 3 would reach an AH
SDS of 1.0 (95% PI between 2.2 and 0.2) when using the
low dose and0.8 SDS (95% PI between2.0 and 0.4) when
using the high dose of GH. As before, the difference in AH
would be quite small while doubling the costs of treatment.
Obviously, one should keep in mind that the model only
TABLE 4. Examples of predicted AH SDS resulting from the
regression model
GH dose (IU/m2d):
TH SDS  0 TH SDS  1 TH SDS  2
3 6 3 6 3 6
Height SDS at start
2 0.6 0.4 0.9 0.7 1.2 1
3 1 0.8 1.3 1.1 1.6 1.4
4 1.5 1.3 1.8 1.5 2 1.8
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predicts 42% of the difference in AH, leaving 58% of the
variation to be explained by other factors, such as genetic
background (8, 9). For that reason, larger numbers of GH-
treated short SGA children with detailed phenotypic and
genetic data are required to allow for a prediction model with
a higher predictive value.
In conclusion, long-term, continuous GH treatment in
short children born SGA leads to a normalization of height
in childhood and adolescence. Eighty-five percent will reach
a normal AH, whereas 98% will reach an AH within their TH
range. Based on our study we recommend considering GH
treatment for short SGA children without signs of persistent
catch-up growth and who are therefore at risk of significant
height disability as adults. Interestingly, a dose of 3 IU/m2d
proved to be as effective as the higher GH dose of 6 IU/m2d
for most children. Only children with extreme short stature
or/and a TH below the normal range may need a higher GH
dose to normalize height during childhood and in adulthood.
Further studies should aim at optimizing GH treatment by
developing advanced prediction models indicating the best
treatment options for each child.
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